Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	€1.340	+21.82%	1,48,647
13/26/13	€1.100	+22.22%	1,38,133
12/26/12	€0.9000	+21.62%	80,418
11/26/11	€0.7400	+8.82%	4,116
10/26/10	€0.6800	+14.09%	30,385

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris 09:25:00 14/08/2026 pm IST			5-day change	1st Jan Change
1.340 ^EUR	+21.82%		+124.83%	+54.38%

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	28.76L 33.3L 27.03L 24.58L 46.21L 32Cr 46.97L 3.17Cr 1.24Cr 16Cr 1.25Cr 1.22Cr 53Cr	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	39.57L 45.81L 37.18L 33.82L 63.58L 44Cr 64.63L 4.36Cr 1.7Cr 22Cr 1.72Cr 1.68Cr 73Cr	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	99.21%	Yield 2023 *	-	Yield 2024	-

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/24/16	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/24/15	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/23/07	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/23/27	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/23/28	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/23/09	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/22/23	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/22/14	Twitter to shut down newsletter product Revue next year	RE
06/22/06	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
06/22/06	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

03/03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
25/02	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
10/12	Klarsen : ALKLA-Attribution gratuite de BSA	PU
09/12	Klarsen : ALKLA-ACTIVITE 3T2025	PU
27/11	Klarsen : ALKLA-Résultat augmentation de capital	PU

Klarsen Share Price

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Course Extremes

Managers and Directors: Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

Income Statement and Estimates

03/08	Klarsen : Information réglementée – 2026
30/07	Klarsen : ALKLA – Klarsen ouvre une nouvelle séquence et donne rendez-vous à ses actionnaires le 27 août – 30 Juillet 2026
30/07	Klarsen : ALKLA-CP KLARSEN-nouvelle séquence
24/07	Klarsen : ALKLA – Klarsen annonce la résolution amiable de son litige avec la société PADAM – 24 Juillet 2026
24/07	Klarsen : ALKLA-Résolution litige PADAM à l'amiable

1 day	+21.82%
1 week	+124.83%
Current month	+103.03%
1 month	+252.63%
3 months	+131.03%
6 months	+19.11%
Current year	+54.38%

1 week	0.6	1.34
1 month	0.38	1.34
Current year	0.22	1.34
1 year	0.22	1.34
3 years	0.22	4.03
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Jean-Luc Rivière BRD	Director/Board Member	-	26/06/2012
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/03/22	Parrou Julien	Buy		2,617	0.0790%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,000	0.0905%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	+21.82%	+124.83%	+37.86%	-62.46%	51.41L
IBM	-1.19%	-1.25%	-1.18%	+65.12%	22TCr
SNOWFLAKE INC.	-2.51%	-0.48%	+68.76%	+115.18%	11TCr
ACCENTURE PLC	-0.90%	+0.67%	-28.14%	-43.25%	11TCr
TATA CONSULTANCY SERVICES LTD.	-0.59%	-3.74%	-21.88%	-31.56%	8.93TCr
RELX PLC	+1.41%	-3.84%	-28.42%	-2.32%	5.98TCr
INFOSYS LIMITED	-0.49%	-0.50%	-19.24%	-16.10%	4.95TCr
NEC CORPORATION	+5.10%	+6.29%	+14.03%	+266.68%	4.31TCr
FUJITSU LIMITED	+2.43%	+4.52%	+10.15%	+113.03%	4.19TCr
HCL TECHNOLOGIES LIMITED	-0.73%	+0.25%	-8.71%	+16.14%	3.85TCr
Average	+2.83%	+13.31%	+2.32%	+42.05%	7.65TCr
Weighted average by Cap.	+0.14%	+0.09%	+0.81%	+46.94%

	2023	2024
Net sales	50.26L 58.19L 47.23L 42.95L 80.75L 56Cr 82.08L 5.53Cr 2.16Cr 28Cr 2.18Cr 2.14Cr 93Cr	63.11L 73.07L 59.3L 53.93L 1.01Cr 70Cr 1.03Cr 6.95Cr 2.72Cr 35Cr 2.74Cr 2.68Cr 116.27Cr
Net income	27.51L 31.85L 25.85L 23.51L 44.2L 30Cr 44.93L 3.03Cr 1.18Cr 15Cr 1.2Cr 1.17Cr 51Cr	-47.76T -55.3T -44.88T -40.82T -76.74T -52.88L -78.01T -5L -2L -26.48L -2L -2L -88L
Net Debt	-6L -7L -6L -5L -10.19L -7.02Cr -10.36L -69.86L -27.31L -3.52Cr -27.58L -26.98L -12Cr	10.81L 12.51L 10.16L 9L 17.36L 12Cr 17.65L 1.19Cr 46.53L 5.99Cr 46.98L 45.96L 20Cr